Zara Weinberg

Zara Weinberg

Auto-generated profile, based on publicly available information

Zara Weinberg

Department of Biochemistry & Biophysics, UCSF

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

2 February 2019 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MSM. Alexander Stanczyk
M. Alexander Stanczyk
KLKathryn E. Livingston
Kathryn E. Livingston
LCLouise Chang
Louise Chang
ZWZara Y. Weinberg
Zara Y. Weinberg
MPManojkumar A. Puthenveedu
Manojkumar A. Puthenveedu
JTJohn R. Traynor
John R. Traynor
Background and Purpose: The δ‐opioid receptor is an emerging target for the management of chronic pain and depression. Biased signalling, the preferential activation of one signalling pathway over another downstream of δ‐receptors, may generate better therapeutic profiles. BMS 986187 is a positive allosteric modulator of δ‐receptors. Here, we ask if BMS 986187 can directly activate the receptor from an allosteric site, without an orthosteric ligand, and if a signalling bias is generated.Experimental Approach: We used several clonal cell lines expressing δ‐receptors, to assess effects of BMS 986187 on events downstream of δ‐receptors by measuring G‐protein activation, β‐arrestin 2 recruitment, receptor phosphorylation, loss of surface receptor expression, ERK1/ERK2 phosphorylation, and receptor desensitization.Key Results: BMS 986187 is a G protein biased allosteric agonist, relative to β‐arrestin 2 recruitment. Despite showing direct and potent G protein activation, BMS 986187 has a low potency to recruit β‐arrestin 2. This appears to reflect the inability of BMS 986187 to elicit any significant receptor phosphorylation, consistent with low receptor internalization and a slower onset of desensitization, compared with the full agonist SNC80.Conclusions and Implications: This is the first evidence of biased agonism mediated through direct binding to an allosteric site on an opioid receptor, without a ligand at the orthosteric site. Our data suggest that agonists targeting δ‐receptors, or indeed any GPCR, through allosteric sites may be a novel way to promote signalling bias and thereby potentially produce a more specific pharmacology than can be observed by activation via the orthosteric site.

1 July 2011 in Neuroscience Letters
Verified
Journal Article
Closed access
ZWZachary Y. Weinberg
Zachary Y. Weinberg
MNMarjorie L. Nicholson
Marjorie L. Nicholson
PCPaul J. Currie
Paul J. Currie

20 May 2021 in eLife
Verified
Journal Article
Open access
SCStephanie E Crilly
Stephanie E Crilly
WKWooree Ko
Wooree Ko
ZWZara Y Weinberg
Zara Y Weinberg
MPManojkumar A Puthenveedu
Manojkumar A Puthenveedu
The prevailing model for the variety in drug responses is that different drugs stabilize distinct active states of their G protein-coupled receptor (GPCR) targets, allowing coupling to different effectors. However, whether the same ligand generates different GPCR active states based on the immediate environment of receptors is not known. Here we address this question using spatially resolved imaging of conformational biosensors that read out distinct active conformations of the δ-opioid receptor (DOR), a physiologically relevant GPCR localized to Golgi and the surface in neuronal cells. We have shown that Golgi and surface pools of DOR both inhibit cAMP, but engage distinct conformational biosensors in response to the same ligand in rat neuroendocrine cells. Further, DOR recruits arrestins on the surface but not on the Golgi. Our results suggest that the local environment determines the active states of receptors for any given drug, allowing GPCRs to couple to different effectors at different subcellular locations.

13 September 2021 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
NWNicholas B. Woodall
Nicholas B. Woodall
ZWZara Weinberg
Zara Weinberg
JPJesslyn Park
Jesslyn Park
FBFlorian Busch
Florian Busch
RJRichard S. Johnson
Richard S. Johnson
DBDavid Baker
David Baker

31 March 2020 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
RBRenee Bouley
Renee Bouley
ZWZara Y. Weinberg
Zara Y. Weinberg
HWHelen V. Waldschmidt
Helen V. Waldschmidt
YYYu-Chen Yen
Yu-Chen Yen
SLScott D. Larsen
Scott D. Larsen
JTJohn Tesmer
John Tesmer
G protein-coupled receptor (GPCR) kinases (GRKs) play a key role in terminating signals initiated by agonist-bound GPCRs. However, chronic stimulation of GPCRs, such as that which occurs during heart failure, leads to the overexpression of GRKs and maladaptive downregulation of GPCRs on the cell surface. We previously reported the discovery of potent and selective families of GRK inhibitors based on either the paroxetine or GSK180736A scaffold. A new inhibitor, CCG258747, which is based on paroxetine, demonstrates increased potency against the GRK2 subfamily and favorable pharmacokinetic parameters in mice. CCG258747 and the closely related compound CCG258208 also showed high selectivity for the GRK2 subfamily in a kinome panel of 104 kinases. We developed a cell-based assay to screen the ability of CCG258747 and 10 other inhibitors with different GRK subfamily selectivities and with either the paroxetine or GSK180736A scaffold to block internalization of the μ-opioid receptor (MOR). CCG258747 showed the best efficacy in blocking MOR internalization among the compounds tested. Furthermore, we show that compounds based on paroxetine had much better cell permeability than those based on GSK180736A, which explains why GSK180736A-based inhibitors, although being potent in vitro, do not always show efficacy in cell-based assays. This study validates the paroxetine scaffold as the most effective for GRK inhibition in living cells, confirming that GRK2 predominantly drives internalization of MOR in the cell lines we tested and underscores the utility of high-resolution cell-based assays for assessment of compound efficacy. SIGNIFICANCE STATEMENT G protein–coupled receptor kinases (GRKs) are attractive targets for developing therapeutics for heart failure. We have synthesized a new GRK2 subfamily–selective inhibitor, CCG258747, which has nanomolar potency against GRK2 and excellent selectivity over other kinases. A live-cell receptor internalization assay was used to test the ability of GRK2 inhibitors to impart efficacy on a GRK-dependent process in cells. Our data indicate that CCG258747 blocked the internalization of the μ-opioid receptor most efficaciously because it has the ability to cross cell membranes.